Online Quit-Smoking Training for Preventing Smoking Relapse

Recruiting in Palo Alto (17 mi)

Overseen by Myra Muramoto, MD, MPH

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Colorado, Denver

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to assess the effect of the Helpers Stay Quit training on abstinence over time of newly abstinent smokers, and on the interactions they have with their personal network related to smoking and smoking cessation.

Research Team

Myra Muramoto, MD, MPH

Principal Investigator

University of Colorado School of Medicine

Eligibility Criteria

This trial is for adults over 18 who smoke cigarettes, have quit smoking for 14-45 days, and are proficient in English. Participants need Internet access and must be willing to send weekly texts, complete online surveys, self-collect a blood sample, and possibly do an interview. They can't have had cessation training in the past 2 years.

Inclusion Criteria

Willing to self-collect dried blood spot and send back to research team

Willing and able to send/receive weekly text messages using personal mobile phone plan

I have not smoked for 2 to 8 weeks.

Exclusion Criteria

I haven't had any cessation training in the last 2 years.

Treatment Details

Interventions

• Helpers Stay Quit Training (Behavioral Intervention)

Trial Overview The study tests the Helpers Stay Quit online training program's effectiveness on maintaining non-smoking status among recent quitters and its impact on their social interactions regarding smoking habits.

Participant Groups

Group I: Helpers Stay Quit Training Experimental Treatment 1 Intervention

Research participants randomized to the experimental arm will receive the on-line Helpers Stay Quit training which provides training on how to help others quit smoking.

Group II: Usual Care Active Control 1 Intervention

Research participants randomized to the arm without intervention will receive Quitline usual care. They will be contacted for assessment of abstinence at 7 months after enrollment in services. If the participant has relapsed, the Quitline will attempt to re-engage the participant in cessation services (telephone and/or web-based).

Who Is Running the Clinical Trial?

University of Colorado, Denver

Lead Sponsor

Trials

1,842

Recruited

3,028,000+

Aviva Abosch

University of Colorado, Denver

Chief Medical Officer since 2019

MD

Uday B. Kompella

University of Colorado, Denver

Chief Executive Officer since 2015

PhD in Pharmaceutical Sciences

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School